FDAnews Announces — Chinese Medicine: The Dangers of Deployment Webinar, Nov. 29, 2018

China’s goal is to be the world’s pharmacy. FDAnews has called on Rosmary Gibson, Senior Advisor at the Hastings Center, to discuss the real-world impact of Chinese medicine on public health and the scrutiny it’s undergoing.

FALLS CHURCH, Va. (PRWEB) November 20, 2018 -- Chinese Medicine: The Dangers of Deployment
The Impact on Pharmaceutical Regulatory and Quality Specialists
**An FDAnews Webinar**
Nov. 29, 2018 — 1:30 p.m. – 3:00 p.m. ET
www.fdanews.com/chinesemedicine

China wants to be the world’s pharmacy.

But troubles abound.

More than half of all valsartan products on the U.S. market have been recalled due to a probable cancer-causing chemical in the API. The recall shines a spotlight on growing U.S. and global dependence on China for APIs and chemical intermediates.

Talk of proposed tariffs on Chinese pharmaceuticals has raised concerns about the impact on the supply and price of drugs. Tariffs could be disruptive to the market since China is the sole global supplier of many APIs and chemical intermediates. Supply chain modification is burdensome and can affect quality and access to an unfettered supply.

FDAnews has called on Rosmary Gibson, Senior Advisor at the Hastings Center and author of China Rx: Exposing the Risks of America’s Dependence on China for Medicine, to discuss the real-world impact of Chinese medicine on public health and the scrutiny it’s undergoing. Attendees will learn the following:

- Three lessons from the valsartan case
- Three questions to ask API suppliers to ensure GMP
- How to determine whether or not Chinese medicine is safe
- How to develop a model and a strategy for determining whether medicines produced by China are safe and effective
- The rationale for proposed tariffs on Chinese medical products
- Details of the industry response to tariffs on Chinese-made APIs and chemical intermediates
- The importance of China’s goal to become the world’s pharmacy and the impact on the global supply chain and regulatory oversight

Register today to understand the risks and challenges posed by U.S. dependence on Chinese pharmaceuticals.

Meet the Presenter:
Rosemary Gibson, Senior Advisor, Hastings Center
Rosemary Gibson writes and lectures about health care, health care reform, Medicare, and patient safety. She led national health care quality and safety initiatives at the Robert Wood Johnson Foundation. She was chief
architect of the foundation’s decade-long strategy that successfully established palliative care in more than 1,600 hospitals in the United States. She is the recipient of the Lifetime Achievement Award from the American Academy of Hospice and Palliative Medicine.

Who Will Benefit:
- Regulatory Affairs
- Quality Assurance
- Supply Chain Managers

Webinar Details:
Chinese Medicine: The Dangers of Deployment
The Impact on Pharmaceutical Regulatory and Quality Specialists
**An FDAnews Webinar**
Nov. 29, 2018 — 1:30 p.m. – 3:00 p.m. ET
www.fdanews.com/chinesemedicine

Tuition:
$287 per site

Easy Ways to Register:
Online: www.fdanews.com/chinesemedicine
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.
Contact Information
Michelle Butler
FDAnews
http://www.fdanews.com
703-538-7600

Online Web 2.0 Version
You can read the online version of this press release here.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb.